<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929745</url>
  </required_header>
  <id_info>
    <org_study_id>15-17769</org_study_id>
    <nct_id>NCT02929745</nct_id>
  </id_info>
  <brief_title>Single Cell Genomics of Psoriatic Skin</brief_title>
  <official_title>Elucidating the Fundamental Differences Between HLA-Cw6 Positive and HLA-Cw6 Negative Psoriasis Skin Lesions, With a Comparison to Healthy Skin, at the Single Cell Level of the Infiltrated Immune Cell Types</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand how genetics play a role in psoriasis.
      Specifically, a genetic allele HLA-Cw6 is known to be associated with psoriasis, and this
      study aims to find out how it affects genetic and protein expression in patients with
      psoriasis, compared to healthy people, at a single-cell level using a novel flow cytometry
      and RNA-sequencing protocol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 1, 2016</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of immune cell population from skin biopsies</measure>
    <time_frame>once</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of diferentially expressed genes from skin biopsies</measure>
    <time_frame>once</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of HLA -cw6 status from blood samples</measure>
    <time_frame>once</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>10 HLA-Cw6+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLA-Cw6+ patients will donate blood and skin samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 HLA Cw6-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLA-Cw6- patients will donate blood and skin samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Skin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy patients will donate blood and skin samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin biopsy</intervention_name>
    <description>Four 4-5 mm punch biopsies of the skin</description>
    <arm_group_label>10 HLA Cw6-</arm_group_label>
    <arm_group_label>10 HLA-Cw6+</arm_group_label>
    <arm_group_label>Healthy Skin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>Blood will be drawn to test for HLA-cw6 status</description>
    <arm_group_label>10 HLA Cw6-</arm_group_label>
    <arm_group_label>10 HLA-Cw6+</arm_group_label>
    <arm_group_label>Healthy Skin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For subjects in the psoriasis group:

          1. Ability to provide written consent and comply with the protocol

          2. At least 18 years of age

          3. Diagnosis of plaque psoriasis for at least 6 months prior to enrollment

          4. BSA &gt; 5% and at least one target plaque on trunk or extremities greater than 10cm2

        For control subjects:

          1. Ability to provide written consent and comply with the protocol

          2. At least 18 years of age

          3. No previous diagnosis of psoriasis or other inflammatory skin conditions

        Exclusion Criteria:

        For subjects in the psoriasis group:

          1. Subject has non-plaque form of psoriasis.

          2. Subject has drug-induced psoriasis.

          3. Pregnancy at any point during the study period.

          4. Known allergy to lidocaine, other local anesthetics, or any component of local
             anesthetic agents.

          5. Known HIV positive status.

          6. Evidence of abnormality of any immune cell population from a drug-induced or genetic
             cause.

          7. Known coagulopathy.

        For control subjects:

          1. Any physical examination findings by the investigators consistent with psoriasis or
             other inflammatory skin conditions.

          2. Pregnancy at any point during the study period.

          3. Known allergy to lidocaine, other local anesthetics, or any component of local
             anesthetic agents.

          4. Known HIV positive status.

          5. Evidence of abnormality of any immune cell population from a drug-induced or genetic
             cause.

          6. Known coagulopathy.

          7. Use of any immunosuppressant or immunomodulating therapies within 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilson Liao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quinn Thibodeaux, MD</last_name>
    <phone>415-944-7618</phone>
    <email>psoriasis@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Psoriasis Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quinn Thibodeaux, MD</last_name>
      <phone>415-944-7618</phone>
      <email>psoriasis@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Wilson Liao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <last_update_submitted>August 1, 2019</last_update_submitted>
  <last_update_submitted_qc>August 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunology, genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

